Alpha 2.0
Login Register
» Authors » Michael Schwenkert

Michael Schwenkert

Explore the profile of Michael Schwenkert including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 385
Followers 0
Related Specialties
Oncology
Allergy & Immunology
Hematology
Top 10 Co-Authors
Georg H Fey
Christian Kellner
Christoph Stein
Bernhard Stockmeyer
Markus Kugler
Kristin Mentz
Domenica Saul
Andreas Mackensen
Ingo Schubert
Katrin Birkholz
Published In
Br J Haematol
MAbs
Melanoma Res
Mol Cancer
Cancer Immunol Immunother
Affiliations
Soon will be listed here.
Recent Articles
1.
A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
Amoury M, Mladenov R, Nachreiner T, Pham A, Hristodorov D, Di Fiore S, et al.
Int J Cancer . 2016 Apr; 139(4):916-27. PMID: 27037627
Chondroitin sulfate proteoglycan 4 (CSPG4) has been identified as a highly promising target antigen for immunotherapy of triple-negative breast cancer (TNBC). TNBC represents a highly aggressive heterogeneous group of tumors...
2.
Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone
Krug C, Birkholz K, Paulus A, Schwenkert M, Schmidt P, Hoffmann N, et al.
Cancer Immunol Immunother . 2015 Oct; 64(12):1623-35. PMID: 26515978
Chimeric antigen receptor (CAR)-modified T cells emerged as effective tools in the immunotherapy of cancer but can produce severe on-target off-tissue toxicities. This risk can conceivably be overcome, at least...
3.
CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes
Kneissl S, Zhou Q, Schwenkert M, Cosset F, Verhoeyen E, Buchholz C
PLoS One . 2013 Nov; 8(11):e79047. PMID: 24244415
B lymphocytes are an important cell population of the immune system. However, until recently it was not possible to transduce resting B lymphocytes with retro- or lentiviral vectors, making them...
4.
A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting
Schubert I, Kellner C, Stein C, Kugler M, Schwenkert M, Saul D, et al.
MAbs . 2012 Feb; 4(1):45-56. PMID: 22327429
To test the hypothesis that dual-targeting confers the novel ability of selective binding to antigen double-positive over antigen single-positive cells, a single-chain triplebody (sctb), HLA-ds16-hu19, was produced and characterized. The...
5.
Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells
Kellner C, Bruenke J, Horner H, Schubert J, Schwenkert M, Mentz K, et al.
Cancer Lett . 2011 Feb; 303(2):128-39. PMID: 21339041
Bispecific scFv antibody-derivatives (bsscFvs) recruiting natural killer (NK) cells for the lysis of malignant cells have therapeutic potential. However, a bsscFv specific for the B-lymphoid tumor antigen CD19 and the...
6.
Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
de Bruyn M, Rybczynska A, Wei Y, Schwenkert M, Fey G, Dierckx R, et al.
Mol Cancer . 2010 Nov; 9:301. PMID: 21092273
Background: Advanced melanoma is characterized by a pronounced resistance to therapy leading to a limited patient survival of ~6 - 9 months. Here, we report on a novel bifunctional therapeutic...
7.
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
Schubert I, Kellner C, Stein C, Kugler M, Schwenkert M, Saul D, et al.
MAbs . 2010 Nov; 3(1):21-30. PMID: 21081841
A single-chain triplebody (sctb) 33-ds16-ds19 comprising two distal single-chain Fv fragments (scFvs) specific for the lymphoid antigen CD19 and the myeloid antigen CD33 flanking a central scFv specific for CD16,...
8.
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
Kugler M, Stein C, Kellner C, Mentz K, Saul D, Schwenkert M, et al.
Br J Haematol . 2010 Jul; 150(5):574-86. PMID: 20636437
Two trivalent constructs consisting of single-chain Fv antibody fragments (scFvs) specific for the interleukin-3 receptor alpha chain (CD123), CD33 and the Fcgamma-receptor III (CD16) were designed and characterized for the...
9.
Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation
Birkholz K, Schwenkert M, Kellner C, Gross S, Fey G, Schuler-Thurner B, et al.
Blood . 2010 Jun; 116(13):2277-85. PMID: 20566893
The use of dendritic cells (DCs) in therapeutic cancer vaccination requires their loading with tumor-specific antigen(s). DEC-205, a phagocytosis receptor mediating antigen uptake, is associated with CD8(+) T-cell responses in...
10.
Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells
Stein C, Kellner C, Kugler M, Reiff N, Mentz K, Schwenkert M, et al.
Br J Haematol . 2010 Jan; 148(6):879-89. PMID: 20064159
Four new single-chain Fv antibody fragments (scFvs) specific for the human leucocyte surface antigen CD123 (interleukin-3 receptor alpha) were generated to achieve preferential targeting of leukaemia stem cells (LSCs) in...